🚨🚨 #Adagrasib 🎯🎯 in patients with #KRAS G12C mutations; tumor agnostic (Non-CRC, Non-NSCLC). ➡️ Median 2 lines of prior therapy ➡️ All Patients: ORR 35%; Median PFS 7.4 months; OS: 14 months ➡️ PDAC ORR 33.3%; DCR: 81% ➡️BTC ORR 42.7%; DCR : 91.7%

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) @DrShubhamPant & Prof. @efratdotan discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of

Had a Gr8 discussion with @rachnatshroff on one of my fav topics: Molecular Profiling in Pancreatic Cancer, with a deep dive into RAS testing and codon-specific interpretation!! 💥 Watch this space—more discussions and insights to come!!! https://t.co/c6tmdEO3pf via @onclive

mPDAC is notoriously aggressive with a poor prognosis. Most patients are diagnosed at an advanced stage and need chemotherapy as soon as possible. In this podcast, Profs. @DrShubhamPant & @efratdotan discuss how to select and optimise first- and second-line chemotherapeutic

Hear @DrShubhamPant and @rachnatshroff discuss how KRAS mutations, long considered “undruggable” in pancreatic cancer, are now emerging as actionable targets, offering new hope for a historically treatment-resistant disease. Watch more here!

@DrShubhamPant kicks off session on clinical data with RAS inhibitors - VERY promising early data! #DAVAGI

🧵 Encouraging early results from @ElicioTx KRAS-targeting vaccine in #pancreaticcancer and colorectal cancer published in @NatureMedicine, feat. co-corresponding authors/@PanCAN SMAB members @DrShubhamPant and @EileenMOReilly. https://t.co/8l86hmcfVO

🔎 mPDAC is notoriously aggressive w/ a poor prognosis Patients are generally Dx’d w/ advanced-stage disease & require chemotherapy as soon as possible New podcast episode from Prof. @DrShubhamPant and Prof. @efratdotan! 📹 Highlights video in this post Listen to the full

Received a Texas sized farewell from my @MDAndersonNews family, complete with an exceptional brisket from top chef @eugenekoay. Thanks to Stacy & Eugene for hosting and the gang for 12 AMAZING years of friendship & collaboration (both keep going!) Grateful to all of you 🙏🏽🙏🏽

Frontline Tx regimens in mPDAC should be individualised based on: 🔸performance status 🔸comorbidities 🔸risk of neuropathy 👉 FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles What else do HCPs need to know about

Had a Gr8 discussion with @rachnatshroff on one of my fav topics: Molecular Profiling in Pancreatic Cancer, with a deep dive into RAS testing and codon-specific interpretation!! 💥 Watch this space—more discussions and insights to come!!! https://t.co/c6tmdEO3pf via @onclive

@TumorBoardTues @DrShubhamPant @MPishvaian @drsmags @NeehaZaidi @rohit_thum @GIMedOnc @ShrutiPatelMD @ryanhuey @SaumyaMaruMDPhD @MadhuEluri @ebludmir @DanZhaoMD @GIcancerDoc @CentralParkWMD @marklewismd @Aiims1742 @ArndtVogel @OncBrothers 18/18 #TumorBoardTuesday 🎯Key takeaways, cont’d: 💰Financial toxicity of NALIRIFOX = major concern 💩Caution re: increased risk of GI side effects (diarrhea, n/v) 💡May consider NALIRIFOX in select pts due to ⬇️neuropathy + BM suppression

@TumorBoardTues @DrShubhamPant @MPishvaian @drsmags @NeehaZaidi @rohit_thum @GIMedOnc @ShrutiPatelMD @ryanhuey @SaumyaMaruMDPhD @MadhuEluri @ebludmir @DanZhaoMD @GIcancerDoc @CentralParkWMD @marklewismd @Aiims1742 @ArndtVogel @OncBrothers 7/18 #TumorBoardTuesday 🌍 NAPOLI-3: randomized, open-label, global Ph3 trial (n=770) @LancetOncol ⚖️ NALIRIFOX > Gem+nab-P in 1L metastatic PDAC 🟢 Median OS: 11.1 mos 🆚 9.2 mos (HR 0.83; p=0.036) 🟢 Median PFS: 7.4 mos 🆚 5.6 mos (HR 0.70; p<0.0001) 🟡 ORR: 41.8%

Excited for the discussion

@TumorBoardTues 1/18 #TumorBoardTuesday #OncTwitter Today’s case: 61 yo 👩🏻, professional violinist 🎻 Abdominal pain + weight loss x 3 months ECOG 1 CT A/P: 3.2-cm pancreatic head mass, +liver lesions

📣 GI CONNECT podcast episode 📣 ➡️ Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) @DrShubhamPant & Prof. @efratdotan discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of

#TumorBoardTuesday 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer So to put this in context: 📢Join us Tuesday, 07-08-25 at 8PM ET as @DrShubhamPant & @DanielHaldarMD 🗣️Optimizing 1L Treatment Selection in mPDAC RT and bring others into the discussion‼️

And that’s a wrap on #ESMOGI in vibrant Barcelona! Honored to chair the #KRAS in pancreatic cancer symposium, present the COMBAT-Pancreatic Cancer trial, and reconnect with amazing colleagues. Until next time—Adios Barcelona! 🇪🇸 @rachnatshroff

@paulosiqamaral @brian_rini @IntegrityCE @DrRanaMcKay @montypal @katy_beckermann @JVentoMD @mzugman @DrChoueiri @tompowles1 @TiansterZhang @kidneycan @CParkMD @JadChahoud @alantanmd @Uromigos @AlbigesL @SoaresAndrey @dsahil320 @chefaleixomd @JBrugarolas @YuWeiChenMD @HHammersMD #TumorBoardTuesday I hope everyone in the US🇺🇸is able to enjoy a peaceful and festive 4th of July🎆 📢Then we'll see you back here 07/08/2025 as the omnipresent & infamous @DrShubhamPant and the⬆️⭐️@DanielHaldarMD from @MDAndersonNews 🗣️treatment options in #PancreaticCancer

Metastatic pancreatic ductal adenocarcinoma (mPDAC) ➡️ notoriously aggressive ➡️poor prognosis ➡️often diagnosed late ➡️surgery is usually not an option This is why chemotherapy strategies really matter Podcast discussion from Prof. @DrShubhamPant & Prof. @efratdotan Watch

This #ASCO was special as it was a celebration of success of our Junior Faculty and fellows who SHOWED UP!!! Officially in the ranks of “Senior Author” 😄😄😄 #endcancer @ASCO @MDAndersonNews